Clinical trials: Nicotine Adverse Reaction
Oxygen Deficiency, Desaturation of Blood
THRIVE Use in Pediatric Populations- Multi Site
THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
- Conditions
- Oxygen Deficiency, Desaturation of Blood, Hypoventilation, Anesthesia; Adverse Effect
- Trial name
- NCT04322994
- Testing
- Transnasal Humidified Rapid-Insufflation Ventilatory Echange
- Where
- 5 sites in United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Stanford University
Chemo Brain, Chemotherapy-related Cognitive Impairment
Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
The purpose of this study is to evaluate the use of a nicotine patch as a treatment for problems with attention, learning and memory in breast cancer patients who are 1-5 years post chemotherapy.
- Conditions
- Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer
- Trial name
- NCT02312934
- Testing
- Transdermal nicotine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University Medical Center
Oxygen Deficiency, Desaturation of Blood
Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Procedures
THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
- Conditions
- Oxygen Deficiency, Desaturation of Blood, Hypoventilation, Anesthesia; Adverse Effect
- Trial name
- NCT03430206
- Testing
- High-flow nasal cannula
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Stanford University
Breast Cancer, Chemotherapeutic Agent Toxicity
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
- Trial name
- NCT00751101
- Testing
- Nicotine patch
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco